Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhood

Metabolism: Clinical and Experimental

Volumn 60, Issue 6, 2011, Pages 874-880

  Dimock, David ^a   Thomas, Vijaya ^a   Cushing, Anna ^a   Purdy, Julia B ^b,c   Worrell, Carol ^d   Kopp, Jeffrey B ^e   Hazra, Rohan ^c,d   Hadigan, Colleen ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b CLINICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALBUMIN; ANTIRETROVIRUS AGENT; CREATININE; DIDANOSINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INSULIN; INTEGRASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE;

ADOLESCENT; ANTHROPOMETRIC PARAMETERS; ANTIVIRAL THERAPY; ARTICLE; BODY FAT; BODY MASS; CD4 LYMPHOCYTE COUNT; CHILDHOOD; CLINICAL ARTICLE; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLUCOSE HOMEOSTASIS; HOMEOSTASIS; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MALE; MEDICAL ASSESSMENT; METABOLIC DISORDER; METABOLIC PARAMETERS; MICROALBUMINURIA; ORAL GLUCOSE TOLERANCE TEST; PERINATAL PERIOD; PRIORITY JOURNAL; VIRUS LOAD;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ALBUMINURIA; ANTHROPOMETRY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM DISORDERS; LIPODYSTROPHY; LONGITUDINAL STUDIES; MALE; METABOLIC DISEASES; PUBERTY; RISK REDUCTION BEHAVIOR; YOUNG ADULT;

EID: 79956078302     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.08.007     Document Type: Article

References (40)

1. Grinspoon S, Carr A. Cardiovascular risk and body fat abnormalities in HIV-infected adults. N Engl J Med 2005;352:48-62. (Pubitemid 40075680)
2. Schwartz EJ, Szczech LA, Ross MJ, Klotman ME, Winston JA, Klotman PE. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 2005;16:2412-20. (Pubitemid 41725059)
3. Wyatt CM, Klotman PE. HIV-associated nephropathy in the era of antiretroviral therapy. Am J Med 2007;120:488-92. (Pubitemid 46764627)
4. Samaras K. Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection. J Antimicrob Chemother 2008;61:238-45.
5. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the data collection on adverse events of anti-HIV drugs (D:A: D) study. Diabetes Care 2008;31:1224-9.
6. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005;165:1179-84. (Pubitemid 40720744)
7. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35. (Pubitemid 46658704)
8. Grunfeld C, Delaney JA, Wanke C, Currier JS, Scherzer R, Biggs ML, et al. Preclinical atherosclerosis due to HIV infection: carotid intimamedial thickness measurements from the FRAM study. AIDS 2009;23:1841-9.
9. Mondy KE, de las Fuentes L, Waggoner A, Onen NF, Bopp CS, Lassa-Claxton S, et al. Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy. AIDS 2008;22:849-56.
10. Miller TL, Orav EJ, Lipshultz SE, Arheart KL, Duggan C, Weinberg GA, et al. Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1. J Pediatr 2008;153:491-7.
11. Chantry CJ, Hughes MD, Alvero C, Cervia JS, Meyer 3rd WA, Hodge J, et al. Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy. Pediatrics 2008;122:e129-38.
12. Arpadi SM, Cuff PA, Horlick M, Wang J, Kotler DP. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr 2001;27:30-4. (Pubitemid 32587239)
13. Taylor P, Worrell C, Steinberg SM, Hazra R, Jankelevich S, Wood LV, et al. Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens. Pediatrics 2004;114:e235-42.
14. Carter RJ, Wiener J, Abrams EJ, Farley J, Nesheim S, Palumbo P, et al. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis. J Acquir Immune Defic Syndr 2006;41:453-60.
15. Verkauskiene R, Dollfus C, Levine M, Faye A, Deghmoun S, Houang M, et al. Serum adiponectin and leptin concentrations in HIV-infected children with fat redistribution syndrome. Pediatr Res 2006;60:225-30. (Pubitemid 44297598)
16. McComsey GA, O'Riordan M, Hazen SL, El-Bejjani D, Bhatt S, Brennan ML, et al. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS 2007;21:921-7. (Pubitemid 46684323)
17. Ross AC, O'Riordan MA, Storer N, Dogra V, McComsey GA. Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children. Atherosclerosis 2010.
18. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
19. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-47.
20. Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol 2002;13:1034-9. (Pubitemid 34274100)
21. Tresaco B, Bueno G, Moreno LA, Garagorri JM, Bueno M. Insulin resistance and impaired glucose tolerance in obese children and adolescents. J Physiol Biochem 2003;59:217-23.
22. Tresaco B, Bueno G, Pineda I, Moreno LA, Garagorri JM, Bueno M. Homeostatic model assessment (HOMA) index cut-off values to identify the metabolic syndrome in children. J Physiol Biochem 2005;61:381-8. (Pubitemid 41269262)
23. Valerio G, Licenziati MR, Iannuzzi A, Franzese A, Siani P, Riccardi G, et al. Insulin resistance and impaired glucose tolerance in obese children and adolescents from Southern Italy. Nutr Metab Cardiovasc Dis 2006;16:279-84. (Pubitemid 43983096)
24. Aldrovandi GM, Lindsey JC, Jacobson DL, Zadzilka A, Sheeran E, Moye J, et al. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS 2009;23:661-72.
25. Beregszaszi M, Dollfus C, Levine M, Faye A, Deghmoun S, Bellal N, et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr 2005;40:161-8. (Pubitemid 41395714)
26. Jaquet D, Levine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000;14:2123-8.
27. Rosso R, Parodi A, d'Annunzio G, Ginocchio F, Nicolini L, Torrisi C, et al. Evaluation of insulin resistance in a cohort of HIV-infected youth. Eur J Endocrinol 2007;157:655-9. (Pubitemid 350187383)
28. Chantry C, Hughes M, Alvero C, Cervia J, Hodge J, Borum P, et al, editors. Growth and body composition in children beginning or changing antiretroviral therapy. PACTG1010. XVI International AIDS Conference; 2006 August 13-18. Canada: Toronto (ON); 2006.
29. Kamin D, Hadigan C. Hyperlipidemia in children with HIV infection: an emerging problem. Expert Rev Cardiovasc Ther 2003;1:143-50.
30. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000;160:2050-6. (Pubitemid 30437589)
31. Cao JJ, Barzilay JI, Peterson D, Manolio TA, Psaty BM, Kuller L, et al. The association of microalbuminuria with clinical cardiovascular disease and subclinical atherosclerosis in the elderly: the cardiovascular health study. Atherosclerosis 2006;187:372-7. (Pubitemid 43963017)
32. Hallan S, Astor B, Romundstad S, Aasarod K, Kvenild K, Coresh J. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: The HUNT II Study. Arch Intern Med 2007;167:2490-6. (Pubitemid 350254909)
33. Szczech LA, Grunfeld C, Scherzer R, Canchola JA, van der Horst C, Sidney S, et al. Microalbuminuria in HIV infection. AIDS 2007;21:1003-9. (Pubitemid 46684331)
34. Nguyen S, McCulloch C, Brakeman P, Portale A, Hsu CY. Being overweight modifies the association between cardiovascular risk factors and microalbuminuria in adolescents. Pediatrics 2008;121:37-45.
35. Burgert TS, Dziura J, Yeckel C, Taksali SE, Weiss R, Tamborlane W, et al. Microalbuminuria in pediatric obesity: prevalence and relation to other cardiovascular risk factors. Int J Obes (Lond) 2006;30:273-80. (Pubitemid 43237682)
36. Mantzoros CS. Whither recombinant human leptin treatment for HIV-associated lipoatrophy and the metabolic syndrome? J Clin Endocrinol Metab 2009;94:1089-91.
37. Mulligan K, Khatami H, Schwarz JM, Sakkas GK, DePaoli AM, Tai VW, et al. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia. J Clin Endocrinol Metab 2009;94:1137-44.
38. Resino S, Micheloud D, Lorente R, Bellon JM, Navarro ML, Munoz-Fernandez MA. Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy. HIV Med 2010 [epub ahead of print].
39. Dzwonek AB, Novelli V, Schwenk A. Serum leptin concentrations and fat redistribution in HIV-1-infected children on highly active antiretroviral therapy. HIV Med 2007;8:433-8. (Pubitemid 47335266)
40. Blass S, Ellinger S, Vogel M, Ingiliz P, Spengler U, Stehle P, et al. Overweight HIV patients with abdominal fat distribution treated with protease inhibitors are at high risk for abnormalities in glucose metabolism-a reason for glycemic control. Eur J Med Res 2008;13:209-14. (Pubitemid 351877691)